LD-2 disclosure · 1st Quarter - Report
CENTER FOR ADDICTION SCIENCE, POLICY, AND RESEARCH
Client
- Description
- Nonprofit focused on opportunities in policy and practice that can reduce addiction harms
- Location
- Rhode Island · United States of America
Registrant
- Location
- Fairfax, Virginia, United States of America
Lobbying activities
5 issuesHealth Issues
Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD; potential legislation to create a SUD PRV to increase development of and access to new SUD medicines; support for the FDA Commissioners national PRV and related pathways; support for NIH high-impact clinical trials evaluating repuposed off-patent therapeutics and widely used supplements with potential CMMI involvement; support for White House and CMMI exploration of non-opioid acute pain therapeutics. Related language requests in FY27 L-HHS and Ag-FDA appropriations.
Lobbyistsms JENNY CAROLINE DEBERRY
Covered position (ms JENNY CAROLINE DEBERRY): Senior Legislative Assistant/ Legislative Assistant, Congressman John J. Duncan, Jr.; Senior Campaign Finance Analyst/ Campaign Finance Analyst, Federal Election Commission
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS) · Food & Drug Administration (FDA)
Alcohol and Drug Abuse
Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD; potential legislation to create a SUD PRV to increase development of and access to new SUD medicines; support for the FDA Commissioners national PRV and related pathways; support for NIH high-impact clinical trials evaluating repuposed off-patent therapeutics and widely used supplements with potential CMMI involvement; support for White House and CMMI exploration of non-opioid acute pain therapeutics. Related language requests in FY27 L-HHS and Ag-FDA appropriations.